Side effects reported by European consumers for medications for erectile dysfunction

OBJECTIVE: To characterise consumer adverse drug reaction (ADR) reports for phosphodiesterase type 5 (PDE5) inhibitors. METHODS: We included ADR reports submitted by adults to the European ADR database (EudraVigialnce) from 2007 to 2011. ADRs were classified according to type, seriousness and age an...

Descripción completa

Detalles Bibliográficos
Autores principales: Aagaard, Lise, Hansen, Ebba Holme
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2013
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4076906/
https://www.ncbi.nlm.nih.gov/pubmed/24991611
http://dx.doi.org/10.4103/2279-042X.117390
Descripción
Sumario:OBJECTIVE: To characterise consumer adverse drug reaction (ADR) reports for phosphodiesterase type 5 (PDE5) inhibitors. METHODS: We included ADR reports submitted by adults to the European ADR database (EudraVigialnce) from 2007 to 2011. ADRs were classified according to type, seriousness and age and sex of consumers. The unit of analysis was one ADR. FINDINGS: Totally, 328 ADRs were reported for sildenafil and vardenafil, and only 5% of these were serious. The largest number of reported ADRs was found for sildenafil, i.e., “lack of efficacy” and/or “drug efficacy decreased” (n = 134) and “headache” (n = 21). CONCLUSION: ADRs reported by consumers for PDE5 inhibitors were relatively low, and only few ADRs were serious.

Ejemplares similares